Display options
Cite
Emaduddin M, Edelmann MJ, Kessler BM, et al. Odin (ANKS1A) is a Src family kinase target in colorectal cancer cells. Cell Commun Signal. 2008;6:7doi: 10.1186/1478-811X-6-7.
Emaduddin, M., Edelmann, M. J., Kessler, B. M., & Feller, S. M. (2008). Odin (ANKS1A) is a Src family kinase target in colorectal cancer cells. Cell communication and signaling : CCS, 67. https://doi.org/10.1186/1478-811X-6-7
Emaduddin, Muhammad, et al. "Odin (ANKS1A) is a Src family kinase target in colorectal cancer cells." Cell communication and signaling : CCS vol. 6 (2008): 7. doi: https://doi.org/10.1186/1478-811X-6-7
Emaduddin M, Edelmann MJ, Kessler BM, Feller SM. Odin (ANKS1A) is a Src family kinase target in colorectal cancer cells. Cell Commun Signal. 2008 Oct 09;6:7. doi: 10.1186/1478-811X-6-7. PMID: 18844995; PMCID: PMC2584000.
Copy Download .nbib Format: NLM
Share it on

Cell Commun Signal. 2008 Oct 09;6:7. doi: 10.1186/1478-811X-6-7.

Odin (ANKS1A) is a Src family kinase target in colorectal cancer cells.

Cell communication and signaling : CCS

Muhammad Emaduddin, Mariola J Edelmann, Benedikt M Kessler, Stephan M Feller

Affiliations

  1. Cell Signalling Group, Department of Molecular Oncology, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford University, Headley Way, Oxford OX3 9DS, UK. [email protected].

PMID: 18844995 PMCID: PMC2584000 DOI: 10.1186/1478-811X-6-7

Abstract

BACKGROUND: Src family kinases (SFK) are implicated in the development of some colorectal cancers (CRC). One SFK member, Lck, is not detectable in normal colonic epithelium, but becomes aberrantly expressed in a subset of CRCs. Although SFK have been extensively studied in fibroblasts and different types of immune cells, their physical and functional targets in many epithelial cancers remain poorly characterised.

RESULTS: 64 CRC cell lines were tested for expression of Lck. SW620 CRC cells, which express high levels of Lck and also contain high basal levels of tyrosine phosphorylated (pY) proteins, were then analysed to identify novel SFK targets. Since SH2 domains of SFK are known to often bind substrates after phosphorylation by the kinase domain, the LckSH2 was compared with 14 other SH2s for suitability as affinity chromatography reagent. Mass spectrometric analyses of LckSH2-purified pY proteins subsequently identified several proteins readily known as SFK kinase substrates, including cortactin, Tom1L1 (SRCASM), GIT1, vimentin and AFAP1L2 (XB130). Additional proteins previously reported as substrates of other tyrosine kinase were also detected, including the EGF and PDGF receptor target Odin. Odin was further analysed and found to contain substantially less pY upon inhibition of SFK activity in SW620 cells, indicating that it is a formerly unknown SFK target in CRC cells.

CONCLUSION: Rapid identification of known and novel SFK targets in CRC cells is feasible with SH2 domain affinity chromatography. The elucidation of new SFK targets like Odin in epithelial cancer cells is expected to lead to novel insight into cancer cell signalling mechanisms and may also serve to indicate new biomarkers for monitoring tumor cell responses to drug treatments.

References

  1. Nat Rev Mol Cell Biol. 2007 Aug;8(8):645-54 - PubMed
  2. Mol Cell Biol. 2000 Dec;20(23):9018-27 - PubMed
  3. J Biol Chem. 2007 Jun 1;282(22):16401-12 - PubMed
  4. Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5860-5 - PubMed
  5. Mol Syst Biol. 2006;2:54 - PubMed
  6. Rapid Commun Mass Spectrom. 2006;20(14):2074-80 - PubMed
  7. Mol Cell. 2006 Jun 23;22(6):851-68 - PubMed
  8. Cancer Res. 2006 Mar 1;66(5):2834-43 - PubMed
  9. Nature. 2006 Jan 12;439(7073):168-74 - PubMed
  10. Rapid Commun Mass Spectrom. 2005;19(23):3420 - PubMed
  11. J Biol Chem. 2005 Jul 29;280(30):27705-12 - PubMed
  12. FASEB J. 2005 May;19(7):795-7 - PubMed
  13. Cell. 2005 Apr 22;121(2):271-80 - PubMed
  14. Blood. 2005 Feb 1;105(3):1106-13 - PubMed
  15. Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2358-62 - PubMed
  16. Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):692-7 - PubMed
  17. J Biol Chem. 2007 Dec 28;282(52):37669-77 - PubMed
  18. Clin Cancer Res. 2007 Dec 15;13(24):7232-6 - PubMed
  19. Cell. 2007 Dec 14;131(6):1190-203 - PubMed
  20. Anticancer Agents Med Chem. 2007 Nov;7(6):651-9 - PubMed
  21. Biochem J. 2007 Dec 15;408(3):297-315 - PubMed
  22. Science. 2007 Nov 16;318(5853):1108-13 - PubMed
  23. Mol Cell Biol. 2007 Dec;27(23):8113-26 - PubMed
  24. Exp Cell Res. 2007 Sep 10;313(15):3175-88 - PubMed
  25. J Mol Biol. 2005 Jan 7;345(1):1-20 - PubMed
  26. J Virol. 1999 Jun;73(6):4631-9 - PubMed
  27. Oncogene. 1998 Jul 16;17(2):255-60 - PubMed
  28. J Cell Sci. 1998 Jul 30;111 ( Pt 14):1973-80 - PubMed
  29. J Med Chem. 1997 Oct 24;40(22):3601-16 - PubMed
  30. Oncogene. 1997 Feb 6;14(5):507-13 - PubMed
  31. J Biol Chem. 1996 Mar 15;271(11):6333-41 - PubMed
  32. EMBO J. 1994 May 15;13(10):2341-51 - PubMed
  33. Oncogene. 1995 Apr 20;10(8):1465-73 - PubMed
  34. Curr Biol. 1995 Mar 1;5(3):296-305 - PubMed
  35. Cell. 1993 Mar 12;72(5):767-78 - PubMed
  36. Mol Cell Biol. 1991 Oct;11(10):5113-24 - PubMed
  37. J Cell Biol. 1990 Nov;111(5 Pt 1):1959-70 - PubMed
  38. Cell. 1981 Apr;24(1):165-74 - PubMed
  39. Cancer Res. 1976 Dec;36(12):4562-9 - PubMed
  40. Anal Biochem. 1976 May 7;72:248-54 - PubMed
  41. Cancer Metastasis Rev. 2003 Dec;22(4):337-58 - PubMed
  42. Biochem J. 2003 Apr 1;371(Pt 1):199-204 - PubMed
  43. Oncogene. 2002 Nov 14;21(52):8029-36 - PubMed
  44. Nat Rev Mol Cell Biol. 2001 Jun;2(6):467-75 - PubMed
  45. Mol Cell. 2007 Jun 22;26(6):899-915 - PubMed

Publication Types

Grant support